Skip to main content
OpenTrials
Completed

NCT Number: NCT03697434

Acceptability of Palliative Care in Parkinson Disease Care

This study will assess the feasibility of using specific criteria to standardize the referral of individuals with Parkinson disease to a group of medical providers known as palliative care specialists. Palliative care specialists provide supportive care to individuals living with serious illnesses. The specialty focuses on providing relief from the symptoms and stress of serious illness.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

URMC Neurology; 919 Westfall Rd, Building C

Rochester, New York, 14618, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Subjects with Parkinson disease:

Inclusion criteria

  • Diagnosis of idiopathic PD confirmed as most likely diagnosis with participant's treating provider
  • 18 years of age or older
  • Participant or care partner able to provide informed consent
  • Presence of one or more of the following:

Uncontrolled symptoms (over prior week):

  • Depression
  • Pain
  • Fatigue

Critical events (over prior 6 months):

  • ≥3 falls
  • Unintended weight loss
  • Wheelchair dependence (>50% of time)

Exclusion criteria

  • Diagnosis of atypical or secondary parkinsonism
  • Outpatient palliative care visit scheduled or within the prior 6 months of the screening visit

Subjects who are care partners:

Inclusion criteria

  • Care partner of enrolled participant in the study
  • 18 years of age or older
  • Able to provide informed consent

Exclusion criteria

  • No care partner specific exclusion criteria

Treatment and study plan

Palliative Care referral

Behavioral

Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.

Primary outcomes

  1. Proportion of enrolled participants who have at least 1 visit with a palliative care provider within 3 months of referral

    Time frame: 3 months

    We will assess the feasibility of standardized referral to palliative care by calculating the proportion of enrolled participants with Parkinson disease who have at least 1 visit with a palliative care provider within 3 months of referral.

Secondary outcomes

  1. Change in mean symptom burden

    Time frame: Baseline to 3 months

    Symptom burden will be measured using the Edmonton Symptom Assessment Scale-Revised for Parkinson Disease (ESAS-R: PD), which measures the severity of 14 symptoms on a 1-10 scale. Scores range from 0-140 with higher scores indicating higher symptom burden.

  2. Change in mean quality of life as assessed by the Quality of Life-Alzheimer Disease questionnaire (QoL-AD)

    Time frame: Baseline to 3 months

    Quality of life will be measured using the Quality of Life-Alzheimer Disease questionnaire, which is a 13-item measure that assesses overall quality of life with a focus on physical, social, psychological, and spiritual well-being. Scores range from 13-52 with higher scores indicating better quality of life.

  3. Change in mean caregiver burden

    Time frame: Baseline to 3 months

    Caregiver burden will be measured using the Zarit Burden interview, which is a 22-item questionnaire that assesses caregiver fear, anger, guilt, perspective, hope, and overall quality of life. Scores range from 0-88 with a score of 0-21 associated with little or no burden, 21-40 mild to moderate burden, 41-60 moderate to severe burden, and 61-88 severe burden.

  4. Change in mean caregiver self-efficacy

    Time frame: Baseline to 3 months

    Caregiver self-efficacy will be measured using the Revised Scale for Caregiver Self-efficacy, which is a 15-item questionnaire with 3 sub-sections (self-efficacy for obtaining respite, self-efficacy for responding to disruptive patient behaviors, and self-efficacy for controlling upsetting thoughts about caregiving). Respondents rate their certainty of being able to complete each task from 0% (cannot perform task at all) to 100% (certain that task can be performed). Scores on each of the sub-sections range from 0-500 with a higher score indicating greater self-efficacy.

  5. Barriers to palliative care referral

    Time frame: Baseline

    Barriers to palliative care referral will be measured using a novel qualitative survey that assesses perceived barriers to referral and drivers of desire for referral to palliative care among those with Parkinson disease. The measure includes a qualitative survey of 9 potential barriers to consultation and 5 potential reasons to undergo consultation. Respondents can select as many barriers or reasons as applicable to their perception of referral and can provide free text responses. Overall frequency of selection of each identified barrier among participants will be assessed both at baseline and at 3 months following palliative care referral. Barriers and reasons for referral with higher frequency will be considered to be more important in hindering or driving desire for referral, respectively.

  6. Barriers to palliative care referral

    Time frame: 3 months

    Barriers to palliative care referral will be measured using a novel qualitative survey that assesses perceived barriers to referral and drivers of desire for referral to palliative care among those with Parkinson disease. The measure includes a qualitative survey of 9 potential barriers to consultation and 5 potential reasons to undergo consultation. Respondents can select as many barriers or reasons as applicable to their perception of referral and can provide free text responses. Overall frequency of selection of each identified barrier among participants will be assessed both at baseline and at 3 months following palliative care referral. Barriers and reasons for referral with higher frequency will be considered to be more important in hindering or driving desire for referral, respectively.

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • American Academy of Neurology

Registry information

Official study title

Pilot to Assess the Acceptance of Palliative Care Referral Among Those With Parkinson Disease

Acronym: Palliate-PD

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Oct 5, 2018
Registry last updated
Dec 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.